Antigenic evolution of SARS coronavirus 2

Anna Z. Mykytyn, Ron AM Fouchier, Bart L. Haagmans*

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

13 Citations (Scopus)
52 Downloads (Pure)

Abstract

SARS coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, emerged in China in December 2019. Vaccines developed were very effective initially, however, the virus has shown remarkable evolution with multiple variants spreading globally over the last three years. Nowadays, newly emerging Omicron lineages are gaining substitutions at a fast rate, resulting in escape from neutralization by antibodies that target the Spike protein. Tools to map the impact of substitutions on the further antigenic evolution of SARS-CoV-2, such as antigenic cartography, may be helpful to update SARS-CoV-2 vaccines. In this review, we focus on the antigenic evolution of SARS-CoV-2, highlighting the impact of Spike protein substitutions individually and in combination on immune escape.

Original languageEnglish
Article number101349
JournalCurrent Opinion in Virology
Volume62
DOIs
Publication statusPublished - Oct 2023

Bibliographical note

Funding Information:
This work was financially supported by the Health∼Holland grant LSHM19136 , co-funded by the PPP Allowance made available by the Health∼Holland, Top Sector Life Sciences & Health , to stimulate public–private partnerships, and the European Union's Horizon 2020 research and innovation program under grant number 874735 (VEO). BLH and RAMF are supported by the National Institute of Allergy and Infectious Diseases (NIH/NIAID) Centers of Excellence for Influenza Research and Response under contract 75N93021C00014 — Icahn School of Medicine at Mt Sinai. This paper was part of the research program of the Netherlands Centre for One Health.

Publisher Copyright:
© 2023 The Authors

Fingerprint

Dive into the research topics of 'Antigenic evolution of SARS coronavirus 2'. Together they form a unique fingerprint.

Cite this